Literature DB >> 7975852

Vaccination against Staphylococcus aureus mastitis: immunological response of mice vaccinated with fibronectin-binding protein (FnBP-A) to challenge with S. aureus.

W Mamo1, P Jonsson, J I Flock, M Lindberg, H P Müller, T Wadström, L Nelson.   

Abstract

Mice were immunized with fusion proteins encompassing the fibronectin-binding domain of a staphylococcal fibronectin-binding protein (FnBP-A). A specific antibody response against the fibronectin-binding part of the fusion proteins was detected in the serum of all vaccinated animals. The protective potential of these vaccinations was evaluated in a mouse mastitis model, using Staphylococcus aureus, strain SA113, for challenge. The mice vaccinated with FnBP fusion proteins showed a decreased number of bacteria recovered from the mammary glands and significantly reduced cases of severe mastitis. Histopathological examination of tissue from challenged glands of vaccinated mice revealed either no pathological reactions or disseminated inflammatory reactions with focal necrosis whereas four of six examined tissues from challenged glands of non-vaccinated animals showed total necrosis. A combination of FnBP fusion protein with staphylococcal alpha-toxoid did not increase the efficacy of the vaccination and animals vaccinated with alpha-toxoid alone were as sensitive to challenge as those from the non-vaccinated control group. Thus vaccination of mice with recombinant FnBP resulted in significant protection against challenge with S. aureus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975852     DOI: 10.1016/0264-410x(94)90333-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis.

Authors:  E B Hume; J J Dajcs; J M Moreau; R J O'Callaghan
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Fibronectin-binding protein of Streptococcus equi subsp. zooepidemicus.

Authors:  H Lindmark; K Jacobsson; L Frykberg; B Guss
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

3.  Development of Antistaphylococcal Vaccines.

Authors:  Jean C. Lee
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

Review 4.  Targeting mucosal immunity in the battle to develop a mastitis vaccine.

Authors:  Mini Bharathan; Isis K Mullarky
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-04       Impact factor: 2.673

5.  IL-17A plays an important role in protection induced by vaccination with fibronectin-binding domain of fibronectin-binding protein A against Staphylococcus aureus infection.

Authors:  Kouji Narita; Krisana Asano; Akio Nakane
Journal:  Med Microbiol Immunol       Date:  2017-04-04       Impact factor: 3.402

Review 6.  Cowpea mosaic virus as a vaccine carrier of heterologous antigens.

Authors:  F R Brennan; T D Jones; W D Hamilton
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

7.  Immunorelevant proteins for the diagnosis of bovine staphylococcal mastitis.

Authors:  M H Fabres-Klein; R C Klein; S O De Paula; A O B Ribon
Journal:  World J Microbiol Biotechnol       Date:  2013-02-06       Impact factor: 3.312

8.  Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues.

Authors:  Emanuela Calabi; Franco Calabi; Alan D Phillips; Neil F Fairweather
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice.

Authors:  Carlos Arrecubieta; Iwao Matsunaga; Tomohiro Asai; Yoshifumi Naka; Mario C Deng; Franklin D Lowy
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

10.  Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus.

Authors:  Eva Glowalla; Bettina Tosetti; Martin Krönke; Oleg Krut
Journal:  Infect Immun       Date:  2009-04-13       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.